Exploring the efficacy and safety of rivaroxaban to support elective percutaneous coronary intervention

Update Il y a 4 ans
Reference: EUCTR2011-001094-58

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

The aim of this study is to assess whether rivaroxaban, as compared to unfractionated heparin, on the background of standard dual antiplatelet therapy (DAPT), can effectively suppress thrombosis, and related adverse ischemic events, upon balloon inflation and stent expansion, during elective PCI, without increasing bleeding.


Inclusion criteria

  • Symptomatic CAD patients due to undergo an elective (non emergent) Percutaneous Coronary Intervention (PCI) on one or two lesions in the native coronary vessel(s)